Umea, Sweden—As many as one in five patients undergoing systemic treatment for psoriasis, including oral medications as well as injections or infusions, are not getting sufficient relief, according to a study recently published in the Journal of Dermatological Treatment. Researchers at Umeå University and the Swedish Institute for Health Economics suggest that more psoriasis patients need access to currently available biologic agents, as well as other new and more efficacious treatments. The study was based on PsoReg, which is the Swedish quality register for systemic treatment of psoriasis, and involved 2,646 patients who had been receiving systemic treatment for at least 3 months. Compared to the larger patient group, the subgroup of patients with suboptimal therapy response tended to be younger and have BMI. They were also more often suffering from psoriasis arthritis and were more often smokers.
« Click here to return to The MTM Review.